Yuhan Corporation announced on September 1 that it has signed a memorandum of understanding (MOU) with the Daegu-Gyeongbuk Medical Innovation Foundation (K-MediHub) to strengthen its innovative drug pipeline. The two parties plan to accelerate their open innovation strategy through joint research on new drug candidates and the exchange of research personnel and equipment.
This agreement aims to combine Yuhan's drug development capabilities with K-MediHub's advanced research infrastructure to expand opportunities for discovering promising drug candidates and enhance the competitiveness of the national pharmaceutical and bio industry.
Yuhan Corporation invests about 10% of its annual revenue in research and development (R&D) and has pursued both in-house research and external technology acquisition. Following the success of its lung cancer treatment, Lecsuna, the company has continued to prioritize open innovation as a key growth strategy.
Through this MOU, the two organizations will identify and conduct joint research projects, exchange talented researchers, and strengthen their R&D capabilities. They will also support each other's research facilities and advanced equipment. Additionally, they plan to establish a collaborative network in the medical industry.
In particular, Yuhan Corporation intends to leverage K-MediHub's specialized research personnel and infrastructure to enhance its open innovation strategy and expand into practical joint research and technology collaboration based on specific cooperation needs.
Kim Yeol-hong, head of R&D at Yuhan Corporation, stated, "Collaboration that organically links diverse research capabilities and infrastructure is crucial for developing innovative drugs. I hope that effectively combining the strengths of both organizations will lead to the discovery of promising drug development projects and the creation of research and development outcomes."
Meanwhile, according to Yuhan Corporation's semi-annual report, the company invested 1.222 trillion won in R&D, which is 10.5% of its revenue of 11.662 trillion won for the first half of the year. This represents a 13.8% increase compared to the same period last year.
This agreement aims to combine Yuhan's drug development capabilities with K-MediHub's advanced research infrastructure to expand opportunities for discovering promising drug candidates and enhance the competitiveness of the national pharmaceutical and bio industry.
Yuhan Corporation invests about 10% of its annual revenue in research and development (R&D) and has pursued both in-house research and external technology acquisition. Following the success of its lung cancer treatment, Lecsuna, the company has continued to prioritize open innovation as a key growth strategy.
Through this MOU, the two organizations will identify and conduct joint research projects, exchange talented researchers, and strengthen their R&D capabilities. They will also support each other's research facilities and advanced equipment. Additionally, they plan to establish a collaborative network in the medical industry.
In particular, Yuhan Corporation intends to leverage K-MediHub's specialized research personnel and infrastructure to enhance its open innovation strategy and expand into practical joint research and technology collaboration based on specific cooperation needs.
Kim Yeol-hong, head of R&D at Yuhan Corporation, stated, "Collaboration that organically links diverse research capabilities and infrastructure is crucial for developing innovative drugs. I hope that effectively combining the strengths of both organizations will lead to the discovery of promising drug development projects and the creation of research and development outcomes."
Meanwhile, according to Yuhan Corporation's semi-annual report, the company invested 1.222 trillion won in R&D, which is 10.5% of its revenue of 11.662 trillion won for the first half of the year. This represents a 13.8% increase compared to the same period last year.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.